

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Richard A. SCHUMACHER et al.

Serial No.: 10/622,833 Group Art Unit: 1626

Filed: July 21, 2003 Examiner: R. L. Anderson

For: PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE

AND DIPHENYLAMINE ANALOGS

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

## Timing and Fees

$\boxtimes$	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this inform disclosure statement is filed:					
			three months of the filing date of a national application other than a CPA § 1.53(d);			
			three months of the actual filing date of the national phase of a PCT ation; OR			
	$\boxtimes$	before RCE).	the mailing of a first substantive office action (including after filing of an			
			R. § 1.97(c), this information disclosure statement is filed after the periods C.F.R. § 1.97(b), but before the mailing date of:			
			a final rejection under 37 C.F.R. 1.113;			
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			

			a notice of allowance under 37 C.F.R. § 1.311; and
		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
			a notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed o	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
Statem	nents U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited 1	<u>Materia</u>	<u>ls</u>	
		anceste	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
			of materials listed but not attached were cited in an international search dated

	] Cop	ies of the materials listed are attached.
Non-Eng	lish Langı	lage References
		English-language search report or equivalent paper from a foreign patent ce is provided indicating the relevance of the cited reference(s).
		oreign-language search report from a foreign patent office is provided, and inent parts are translated substantively below:
	X = Y =	document of particular relevance when it is combined with another such document document defining the general state of the art non-written disclosure intercalated document document document cited to understand the theory or principle underlying the invention patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date cited in the application cited for another reason
	Trar	nslation of other relevant information on foreign search report
Other Info	ormation	
Payment	of Fees D	ue (If Any):
		\$ covering the fee identified above is attached.

	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.
$\boxtimes$	The Commissioner is hereby authorized to charge or credit any overpayment to Deposit
Accou	nt #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Brion P. Heaney, Reg. No., 32,542 Attorney/Agent for Applicants


MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MEMORY-28

Date: September 16, 2005

BPH/rrt



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/622,833 INFORMATION DISCLOSURE Filing Date July 21, 2003 STATEMENT BY APPLICANT Richard A. SCHUMACHER First Named Inventor Group Art Unit 1626 (use as many sheets as necessary) **Examiner Name** Rebecca L. Anderson Sheet of Attorney Docket Number MEMORY-28

U.S. PATENT DOCUMENTS							
Examiner		U.S. Patent Docum	ent Kind Code <sup>2</sup>	Name of Patentee or Applicant	Date of Publication of Cited Document		
Initials *	Cite No.1	Number	(if known)	of Cited Document	MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T <sup>6</sup>
		wo	00/64874			11/2/00		
		wo	00/50402			8/31/00		
		WO	95/20578			8/3/95		
		wo	95/04046			2/9/95		

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.